

AMENDMENTS TO THE CLAIMS

1.-39. (Canceled)

40. (new) An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGF β , said antibody-antigen binding domain comprising;

- (a) a VH domain selected from the group consisting of the 6H1 VH domain of which the amino acid sequence is shown in Figure 2(a)(i) (SEQ ID NO: 6), the 11E6 VH domain of which the amino acid sequence is shown in Figure 2(a)(ii) (SEQ ID NO: 37), the Gold 11-VH domain of which the amino acid sequence is shown in Figure 2(a)(iii) (SEQ ID NO: 116), the 1-G2 VH domain of which the amino acid sequence is shown in Figure 2(a)(v) (SEQ ID NO: 120) and the 1-H6 VH domain of which the amino acid sequence is shown in Figure 2(a)(vi) (SEQ ID NO: 122); and
- (b) a VL domain selected from the group consisting of the 6B1 VL domain of which the amino acid sequence is shown in Fig 2(b)(iii) (SEQ ID NO:43), the 6H1 VL domain of which the amino acid sequence is shown in Fig 2(b)(i) (SEQ ID NO: 39), the 6A5 VL domain of which the amino acid sequence is shown in Fig 2(b)(ii) (SEQ ID NO:41), the 11E6 VL domain of which the amino acid sequence is shown in Fig 2(b)(iv) (SEQ ID NO:45), the 14F12 VL domain of which the amino acid sequence is shown in Fig 2(b)(v) (SEQ ID NO:47) and the 6H1 VL domain of which the amino acid sequence is shown in Fig 2(b)(vi) (SEQ ID NO:124).

41. (new) The antibody or antibody fragment thereof according to claim 40 which is in the form of scFv.

42. (new) The antibody or antibody fragment thereof according to claim 40 which is in the form of a whole antibody.

43. (new) An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGF β , said antibody-antigen binding domain comprising;

- (a) a VH domain comprising the 6H1 VH domain CDRs shown in Figure 19(i), wherein VH CDR1 has the amino acid sequence set forth in SEQ ID NO: 126, VH CDR2 has the amino acid sequence set forth in SEQ ID NO: 127 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 128, and
- (b) a VL domain comprising VL domain CDRs selected from the group consisting of:
 - (i) the 6B1 VL domain CDRs shown in Figure 19(ii), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 129, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 130 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 131,
 - (ii) the 6A5 VL domain CDRs shown in Figure 19(iii), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 132, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 133, and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 134, and
 - (iii) the 6H1 VL CDRs shown in Figure 19(iv), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 135, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 136, and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 137.

44. (new) The antibody or antibody fragment thereof according to claim 43 which is in the form of scFv.

45. (new) The antibody or antibody fragment thereof according to claim 43 which is in the form of a whole antibody.

46. (new) The antibody or antibody fragment thereof according to claim 43 wherein the VH domain is the 6H1 VH domain of which the amino acid sequence is shown in Figure 2(a)(i) (SEQ ID NO: 6).

47. (new) The antibody or antibody fragment thereof according to claim 46 which is in the form of scFv.

48. (new) The antibody or antibody fragment thereof according to claim 46 which is in the form of a whole antibody.

49. (new) The antibody or antibody fragment thereof according to claim 46 wherein the VL domain is selected from the 6B1 VL domain, of which the amino acid sequence is shown in Figure 2(b)(iii) (SEQ ID NO: 43), the 6H1 VL domain, of which the amino acid sequence is shown in Figure 2(b)(i) (SEQ ID NO: 124), and the 6A5 VL domain, of which the amino acid sequence is shown in Figure 2(b)(ii) (SEQ ID NO: 41).

50. (new) The antibody or antibody fragment thereof according to claim 49 which is in the form of scFv.

51. (new) The antibody or antibody fragment thereof according to claim 49 which is in the form of a whole antibody.

52. (new) An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGF β , said antibody-antigen binding domain comprising;

- (a) a VH domain comprising the 6H1 VH domain CDRs shown in Figure 19(i), wherein VH CDR1 has the amino acid sequence set forth in SEQ ID NO: 126, VH CDR2 has the amino acid sequence set forth in SEQ ID NO: 127 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 128, and
- (b) a VL domain comprising the 6B1 VL domain CDRs shown in Figure 19(ii), wherein VL CDR1 has the amino acid sequence set forth in SEQ

ID NO: 129, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 130 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 131.

53. (new) The antibody or antibody fragment thereof according to claim 52 which is in the form of scFv.

54. (new) The antibody or antibody fragment thereof according to claim 52 which is in the form of a whole antibody.

55. (new) An isolated antibody or antibody fragment there of comprising an antibody-antigen binding domain of a human antibody specific for TGF β , said antibody-antigen binding domain comprising the VH domain 6H1 VH of which the amino acid sequence is shown in Figure 2(a)(i) (SEQ ID NO: 6) and the VL domain 6B1 VL, of which the amino acid sequence is shown in Figure 2(b) (iii) (SEQ ID NO: 43).

56. (new) The antibody or antibody fragment thereof according to claim 55 which is in the form of scFv.

57. (new) The antibody or antibody fragment thereof according to claim 55 which is in the form of a whole antibody.

58. (new) A composition which comprises an antibody or antibody fragment thereof as in any one of claims 40, 43, 46, 49, 52 or 55 and an excipient.

59. (new) The antibody or antibody fragment thereof as in any one of claims 40, 43, 46, 49, 52 or 55 which comprises one or more amino acids in addition to those forming said human antibody antigen binding domain.

60. (new) The antibody or antibody fragment thereof according to claim 59 comprising an antibody constant region.

61. (new) The antibody or antibody fragment thereof according to claim 59 which comprises a whole antibody.

62. (new) The antibody or antibody fragment thereof according to claim 60 wherein said antibody constant region is IgG4 isotype.

63. (new) A pharmaceutical composition comprising an antibody or antibody fragment thereof as in any one of claims 40, 43, 46, 49, 52 or 55 and a pharmaceutically acceptable excipient.